Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Sponsor: Pfizer
A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2019 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- Spanish Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Barcelona, Spain , Córdoba, Spain , Donostia / San Sebastian, Spain , Jaén, Spain , Madrid, Spain , Málaga, Spain , Sabadell, Spain , Terrassa, Spain and 1 more location